Cost-effectiveness strategies to treat osteoporosis in elderly women

Academic Article

Abstract

  • Background: Comparing the cost-effectiveness of various antiosteoporotic drugs has not been defined. Methods: We determined the cost-effectiveness of calcitonin, raloxifene, bisphosphates and PTH in a base-case cohort of women aged 65 or older with osteoporosis. After bone densitometry, women were stratified into groups of treatment or no treatment. Our outcome goal was a value of $100,000 or less per quality-adjusted life years (QALY). A sensitivity analysis varied nonvertebral fracture reduction and compliance between the two most effective strategies to test various cost per QALY thresholds. Results: Bisphosphonates displayed the most favorable incremental cost saving and prevented more fractures in our base-case analysis. In a sensitivity analysis, virtually all values of bisphosphonates were under $100,000 per QALY and parathyroid hormone (PTH) was between $100,000 and $200,000 per QALY. Conclusions: Only bisphosphonates are cost-effective for fracture prevention in osteoporotic women aged 65 or older and this economic advantage is also maintained in subsets who have a lower relative risk of future fracture. Copyright © 2006 by The Southern Medical Association.
  • Published In

    Digital Object Identifier (doi)

    Pubmed Id

  • 1987036
  • Author List

  • Pfister AK; Welch CA; Lester MD; Emmett MK; Saville PD; Duerring SA
  • Start Page

  • 123
  • End Page

  • 131
  • Volume

  • 99
  • Issue

  • 2